XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.31

+1.4%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (7636)	11/4/1998 11:14:00 AM
From: Bluegreen	Read Replies (2) of 17367

Does anybody know the number per year of spinal taps done just in the US for detection of infections? If clinicians do this invasive procedure in this setting, what is on their list of probable diagnosis? Now once again what trial is ending soon? What will be the indication for Neuprex usage if approved? Do you have plenty of time to wait for spinal tap results before starting treatment? Is Neuprex a relative safe product? Does it make a difference time wise when you give Neuprex when you have certain types of infections on your list of probable diagnosis? Are these questions clinicians have to face around the world everyday? Now explain to me how this indication for Neuprex if approved will be a "niche" market. Since situation is serious enough for the clinician to do a spinal tap, in my opinion cost of Neuprex would not be at issue.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next